DOCSLIB.ORG

Pfizer UK Wants to Switch Sildenafil

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pfizer UK Wants to Switch Sildenafil Q&A with Spotlight Beware Galderma’s on the new June Risser Serrix competitors page 17 page 8 page 20 Contents PfizerUKwants to 7April 2017 Issue Number 480 switch sildenafil COMPANY NEWS RB exploring sale 3 en in the UK could soon have OTC of Food business Maccess to Pfizer Consumer Health- Alliance in the marketfor deals 4 care’serectile-dysfunction drug sildenafil Stada holds takeover talks 5 –the active ingredient in the blockbuster prescription brand Viagra –ifaswitch ap- Futurasecures Portugal deal 6 plication by thefirm is successful. J&J to kick-start7 According to the Medicines and Health- safety challenge careproducts Regulatory Agency’s(MHRA’s) GENERAL NEWS ARM94 switchconsultation document, Pfizer wants to move sildenafil 50mg film-coated tab- Pfizer wants to switchsildenafilfromPOM to P CHPAeyesmonograph win 10 letsfromprescription-only medicine (POM) Calcipotriol set forUKswitch 12 to pharmacy(P) status. claimed, “as the condition may be an early Med devices rules 13 Sildenafil will be availablefromapharma- warning sign of amore serious underlying con- ripe forpublication cist without aprescription for men aged 18 dition, such as heart disease, which may other- years or older suffering from erectile dysfunction, wise go undetected.” NHS to stop paying 14 ARM94 states.The maximum doseisone tablet It wasestimated that up to 70% of men went forsome OTCdrugs aday,with apack size of up to eight tablets. without, or delayed seekingtreatment. Thiswas MARKETING NEWS potentiallydue to the stigma associatedwiththe Checklist forpharmacists condition, Pfizer said, noting that erectile dysfunc- Chameleon fronts 15 Pharmacistswillbesupplied with achecklist tion could have asignificant impactonaman’s Berocca campaign to determine aman’ssuitability for the product, overall health and wellbeing, and could lead to TheOTCLab grows16 the document adds, with additional advice pro- depression, anxiety,and relationship difficulties. reachofEarClin vided on the product label and leaflet. Furthermore, manymen with erectile dys- RB focuses on Easter 17 Furthermore, all men enquiring after the function bypassed the healthcare system com- drug –including those supplied sildenafil by pletely,Pfizer claimed, and purchased “alterna- Owl promotes Sanofi’s Xyzal 18 apharmacist –will be advised to see their gen- tive therapies from unregistered,illegalsources, REGULARS eral practitioner (GP) for ahealth check. which might supplycounterfeit productscon- Commentingonthe application, Dr Berke- taining no active ingredient, the wrong active Spotlight on –Serrix 8 leyPhillips, Pfizer’sUKmedical director,said ingredientor, worse,potentially toxic and dan- Q&A –with Galderma’s 17 that the“availability of pharmacist-supplied, gerous ingredients”. June Risser non-prescription sildenafil could offer men a The proposed switch has been welcomed by Events –Our regular listing 19 newand additional waytoaccess alegitimate, theRoyal PharmaceuticalSociety (RPS), which long-established, andwell-studied treatment for pointed out that “discussing health problems People –HRA names Wright 23 as chief executive erectile dysfunction”. with patients and advising on the benefits and “Thiscouldhavefurther benefits,” Phillips Continued on page 9 Connect with us on: Twitter LinkedIn OTC-bulletin.com DEVELOP WINNING DISTRIBUTIONSTRATEGIES MARKET REPORTS FROM JAMESDUDLEYMANAGEMENT NEW FOR 2017 OTC DISTRIBUTION IN EUROPE MAILORDER AND INTERNET THE NEW GLOBAL AGENDA PHARMACY IN EUROPE REAPINGTHE BENEFITS OF AN Now in its 10th edition, this in-depth study identifies thefactors driving change in the OMNICHANNEL PRESENCE supply network serving Europe’s non-prescription and OTC self-medication sectors. This expanded fourth edition examines how e-commerce is reshaping the It provides acomprehensive, data-driven pharmacy landscape and playing a analysis of the unfolding strategies required to key role in the omnichannel strategies of achieve competitive success. leading healthcareretailers. OVER 590 PAGES AND300 GRAPHS, TABLES AND COVERS 17 EUROPEAN COUNTRIES AND CONTAINS FIGURES COVER 20 EUROPEAN MARKETS KEY LEARNINGS FROM THE USA AND CHINA ® Download online at www.james-dudley.co.uk JAMES DUDLEY® MANAGEMENT COMPANY NEWS OTC Licensing Agreements Business Strategy AFT grabs RB exploring sale NovaTears of Food business ovaliq’s NovaTears dry-eyes treatment Nwill soon be available across Australasia, eckitt Benckiser (RB) has launched a“strat- afterthe Germany-basedfirmsignedalicens- Regic review” of its “non-core” Food busi- ing deal with AFT Pharmaceuticals. nessasitcontinues to move towards becoming Under the terms of the agreement, NewZea- amore health and hygiene focused company. land-based AFT will launch NovaTears –an In ashort statement, the UK-based fast- OTCmedical device –inAustralia and New moving consumer-goods (FMCG) giantsaid it Zealand. In return, Novaliq will receive an up- wanted to respond to “recent press speculation” front payment and sales royalties. that it wasconsidering putting the Food busi- NovaTears is sold across Europe under the ness up for sale. brandnameEvoTears as atreatment forevapo- “French’sFoodisatrulyfantastic business RB’sFrench’smustard rative dry-eye diseases. with great brands, people and ahistory of out- Rakesh Kapoor, RB’schief executive officer, “Theaddition of NovaTears to our eye-care performance. It is nevertheless non-coretoRB,” saidatthe time the deal wasannounced that it line will be welcomed by doctors and patients commented the firm. eh“W avetherefore decid- wasa“significant step forward in RB’sjourney alike,”commented AFT’schief executive of- ed to initiate astrategic reviewofFood where as aleader in consumer health”. ficer HartleyAtkinson. we will explore all options for this great business”. Acquiring Mead Johnson wasa“natural ex- “The product is afirst-in-class,water-freeand “RB will update the market going forward, tension” to RB’sconsumer health ‘powerbrands’, preservative-free treatment,”Atkinsonpointed when appropriate,”itadded. Kapoor said, adding that Mead Johnson’sgeo- out, “based on Novaliq’sproprietary EyeSol tech- Thefirm’s food brandsinclude French’smus- graphic footprint would strengthen “significant- nology platform.” tard and ketchup and Frank’sRed Hot sauces. ly” RB’sposition in developing markets. “The deal will also help advance our position RB’s reported sales at its Food business up by Expandingont he rationalefor the deal,RB in the lubricating eye-drop market,”Atkinson 5% to £411 million (C481 million) in 2016. Oper- said thatadding MeadJohnson’s “deepunder- explained, “where currently AFT holds the ating profit advanced by 16% to £118 million. standing of anew mother’sjourney”, along with number-four positioninboth Australiaand New Thecompanylaunchedthe strategic review its“well-established relationships with healthcare Zealand. This fits withour strategy of strengthen- as it works to close its US$17.9 billion (C16.8 mil- professionals”, would enhance RB’sreputation ing our market position in categories where we lion) acquisition of US-based Mead Johnson with the“millions of mothers”itreaches through already hold asignificantposition.” (OTC bulletin,17February 2017, page 1). its hygiene education programmes and with the Christian Roesky,Novaliq’schief executive Once the deal is finalised, RB will gain a children’svariationsofNurofen and Mucinex. officer,saidthe firm was“delighted” to col- portfolio of brands which includes the Enfamil, Furthermore, the dealgaveRBaleading po- laborate with AFT. “Weare confident thatdry- Enfagrowand Enfapro infant formulas, the Choco sition in the global infant and children’snutri- eyepatients in Australasia will greatly benefit Milk, Lactumand Sustagen children’snutritional tion category,the companyadded, which was from theuse of NovaTearsand ourpartnership milk supplements, as well as the Nutramigen expected to grow at between3%-5% per an- with AFT.” OTC formula for infants with food allergies. num in the medium-to-long-term. OTC Editor: Matt Stewart Production Editor: Jenna Meredith Advertising Controller: Debi Minal Contributing Editor: DavidWallace Director of Subscriptions: Val Davis Deputy Editor: Tom Gallen Editor-in-Chief: Aidan Fry Group Sales Manager: Rob Coulson Assistant Editor: Marie McEvoy Managing Director: MikeRice Awards Manager: Natalie Cornwell 7April 2017 |Number 480 Editorial enquiries: OTC bulletin, Te rms &Conditions: While due carehas been taken to ensurethe accuracy of 4 Poplar Road, Dorridge,Solihull, These can be viewedinfull at www.OTC-bulletin.com. information contained in this publication, the publisher West Midlands B93 8DB, UK. No partofthis publication maybecopied, reproduced, makes no claim that it is free of errorand disclaims any Website: www.OTC-bulletin.com stored in aretrieval system, distributed or transmittedby liability whatsoeverfor anydecisions or actions taken as aresult ofits contents. Te l: +44 (0)1564 777550 anymeans, including electronic,mechanical, photocopying Fax: +44 (0)1564 777524 or recording, without the prior written permission of ©OTC Publications Ltd. All rights reserved. the publisher,orunder the terms and conditions of Email: [email protected] ® aGlobal Site Licence or of alicence issued by the OTC bulletin is registered as atrademark in the European Community. Advertising enquiries: Copyright Licensing Agency (CLA) in London, UK, or Contact: [email protected] rights bodiesin other countries that have reciprocal ISSN 1350-1097. Subscription enquiries: agreements with the CLA. Companyregistered in England No 2765878. Subscription
Load more

Recommended publications
  • Correlation of Physicochemical Properties of Model Drugs and Aerosol Deposition
    CORRELATION OF PHYSICOCHEMICAL PROPERTIES OF MODEL DRUGS AND AEROSOL DEPOSITION w ANA CATARINA MATOS DE OLIVEIRA A thesis submitted for the degree of Doctor of Philosophy Department of Pharmaceutics The School of Pharmacy, University of London 29-39 Brunswick Square London WC IN 1 AX, UK MARCH 2009 ProQuest Number: 10104755 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104755 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Plagiarism Statement This thesis describes research conducted in the School of Pharmacy, University of London between 2004 and 2008 under the supervision of Prof. Graham Buckton and Dr. Simon Gaisford. I certify that the research described is original and that any parts of the work that have been conducted by collaboration are clearly indicated. I also certify that I have written all the text herein and have clearly indicated by suitable citation any part of this dissertation that has already appeared in publication. Signature Date Abstract Dry powder inhalers (DPIs) are recognized devices for the administration of medicines to the lungs.
    [Show full text]
  • Supply and Demand for Medicines Published in Scotland by the Scottish Parliamentary Corporate Body
    Published 30 June 2020 SP Paper 774 6th Report, 2020 (Session 5) Health and Sport Committee Comataidh Slàinte is Spòrs Supply and demand for medicines Published in Scotland by the Scottish Parliamentary Corporate Body. All documents are available on the Scottish For information on the Scottish Parliament contact Parliament website at: Public Information on: http://www.parliament.scot/abouttheparliament/ Telephone: 0131 348 5000 91279.aspx Textphone: 0800 092 7100 Email: [email protected] © Parliamentary copyright. Scottish Parliament Corporate Body The Scottish Parliament's copyright policy can be found on the website — www.parliament.scot Health and Sport Committee Supply and demand for medicines, 6th Report, 2020 (Session 5) Contents Executive Summary _____________________________________________________1 Introduction ____________________________________________________________4 Engagement___________________________________________________________4 Structure of the report ___________________________________________________5 Background ___________________________________________________________6 Research and development _______________________________________________8 Real-world experience and clinical trials _____________________________________8 Personalised medicine___________________________________________________9 Waste _____________________________________________________________10 Manufacturing technology _____________________________________________10 Preparedness for personalised medicine in the healthcare system ______________10
    [Show full text]
  • Why Humidify? for Pharmaceuticals
    Why humidify? For pharmaceuticals... Humidification and Evaporative Cooling Trusted Technology Nortec humidifiers by Condair are waste and enhance productivity. Some evaporative cooling systems to help used in pharmaceutical processing and of the world’s leading pharmaceutical them meet their production objectives. research facilities around the world manufacturers put their trust to maintain product quality, reduce in Condiar humidification and AstraZeneca, UK Sanofi Aventis Vostok, Russia GlaxoSmithKline, UK TEVA, Russia Elanco, Canada Abbott Laboratories, Ireland Pfizer, UK Roche Penzeberg, Germany Apotex, Canada Boston Scientific, Ireland Eli Lilly, UK Bristol-Myers Squibb, Germany Astellas Pharma Europe, Netherlands Roche Kaiseraugust, Switzerland Promega Corporation, USA TEVA Pharmachemie, Netherlands GE Healthcare, Austria Novo Nordisk Pharmaceuticals Co Ltd, China SPL, USA Laboratorios Bayer, Spain DSM, Netherlands Nobel and World Medicine, Turkey Xian Janssen Pharmaceuticals Ltd, China Pfizer, USA Laboratorios Beechmann, Spain Teva and Taro, Israel Sanofi (Beijing) Pharmaceuticals Co Ltd, China Incyte Pharmaceutical, USA Picking Farma, Spain Neopharma, United Arabic Emirates Beijing Novartis Pharmaceuticals Co Ltd, China Kremers Urban Pharmaceuticals, USA Productos Roche S.A., Spain Spimaco, Saudi Arabia Taizhou Astra Zeneca Pharmaceuticals Co Ltd, China MEDCO/Express Scripts, USA QG Medical Devices, Qatar Purdue Heine Pharmacy, USA Cipla, India St Francis Hospital Pharmacy, USA Lupin, India Beckman Coulter, USA Zydus Cadila,
    [Show full text]
  • The Academy of Medical Sciences 2008 FORUM Annual Lecture the UK Pharmaceutical Industry: What Does the Future Hold?
    The Academy of Medical Sciences 2008 FORUM Annual Lecture The UK pharmaceutical industry: what does the future hold? Academy of Medical Sciences Andrew Witty, CEO, GlaxoSmithKline 10 Carlton House Terrace London, SW1Y 5AH Tel: +44(0)20 7969 5288 Fax: +44(0)20 7969 5298 Email: [email protected] Web: www.acmedsci.ac.uk The Academy of Medical Sciences The Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are converted into healthcare benefits for society. Our Fellows are the UK’s leading medical scientists from hospitals and general practice, academia, industry and the public service. The Academy seeks to play a pivotal role in determining the future of medical science in the UK, and the benefits that society will enjoy in years to come. We champion the UK’s strengths in medical science, promote careers and capacity building, encourage the implementation of new ideas and solutions – often through novel partnerships – and help to remove barriers to progress. The Academy’s FORUM with industry The Academy’s FORUM is an active network of scientists from industry and academia, with representation spanning the pharmaceutical, biotechnology and other health product sectors, as well trade organisations, Research Councils and other major charitable research funders. Through promoting interaction among these groups, the FORUM aims to take forward national discussions on scientific opportunities, technology trends and the associated strategic choices for healthcare and other life-science sectors. The FORUM builds upon what is already distinctive about the Academy: its impartiality and independence, its focus on research excellence across the spectrum of clinical and basic sciences and its commitment to interdisciplinary working.
    [Show full text]
  • MSN2021 004 Voriconazole
    Medicine Supply Notification MSN/2021/004 Voriconazole 200mg powder for solution for infusion Tier 2 - medium impact* Date of issue: 14 January 2021 Summary • Pfizer and Bowmed are currently out of stock of voriconazole 200mg vials. • Bowmed expects resupply w/c 18th January. • Fresenius Kabi remains in stock but cannot support the demands of their non-contracted regions during this period. • Pfizer have sourced an alternative product, packaged for the Saudi Arabian market (English labelled) which can support from w/c 18th January until UK licensed stock is resupplied during the course of February. This stock is unlicensed in the UK. • Specialist importers have indicated that other unlicensed imports can be sourced, lead times vary. Actions Required Trust/Health Board pharmacy procurement teams in Bowmed and Pfizer contracted regions should work with clinical leads and the local Medication Safety Officer (MSO) to ensure the following actions are undertaken where relevant: • review local stock holding of voriconazole 200mg vials against anticipated demand and identify if the organisation will need additional supply to bridge the gap until their supplier is back in stock; • work with their Regional Pharmacy Procurement Specialist (RPPS) to share stock locally, to ensure continuity of care for patients; • consider switching patients to oral voriconazole or using an alternative antifungal agent where clinically appropriate; • if therapeutic switching is not possible/appropriate place orders for imports; and • if Trusts are likely to have multiple unlicensed products in use within the organisation at the same time consideration is given and mitigations put in place to minimise the risk of product confusion and dosing errors.
    [Show full text]
  • Cphi Annual Industry Report 2019
    New modalities, new methods and new thinking to solve old problems Industry Expert Panel Submissions CPhI Annual Industry Report 2019 Released at CPhI Worldwide, 5 - 7 November, 2019 Frankfurt, Germany www.cphi.com The CPhI Annual Report is a comprehensive and critically important publication that analyses key trends and innovations forecast by our panel of world class experts. Running as a series of opinions and articles, the CPhI experts call upon their considerable commercial and technical acumen to prophesize the future direction, technologies, opportunities and threats in pharma. It’s an essential read for executives who wish to get a head start today on the shape of tomorrow’s industry. Contents CPhI’s Pharma Industry Rankings: Evaluation of current Pharma ...................................................................................... 3 Part 1. Innovation, AI and Regulation Building Quality into Pharma Manufacturing, from Molecule to Medicine: Pharma 4.0 .........................................12 BIKASH CHATTERJEE, PRESIDENT AND CHIEF SCIENCE OFFICER, PHARMATECH ASSOCIATES Chaos to Continual Improvement: Path to Harmonization ................................................................................................20 AJAZ HUSSEIN PHD, THE NATIONAL INSTITUTE FOR PHARMACEUTICAL TECHNOLOGY & EDUCATION, INC., USA Pharmaceutical Quality: Concepts, Misconceptions, Realities And Remedies ............................................................31 GIRISH MALHOTRA PRESIDENT AT EPCOT INTERNATIONAL Part 2. Biologics (Capacity
    [Show full text]
  • Drug Discovery: a History
    ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery ________________________________________________________________________________________________________________________ ______________________________ Drug Discovery A History Walter Sneader School of Pharmacy University of Strathclyde, Glasgow, UK Copyright u 2005 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to [email protected], or faxed to (+44) 1243
    [Show full text]
  • 2018-Annual-Report.Pdf
    Contents Welcome from the Chair ................................................................................................................................................................. 3 Treasurer’s Report ........................................................................................................................................................................... 5 Membership Report ......................................................................................................................................................................... 6 Partnership Report ........................................................................................................................................................................... 7 Commercial Report .......................................................................................................................................................................... 8 Careers & Academic Liaision Committee (CALC) ...................................................................................................................... 9 External Affairs ............................................................................................................................................................................... 11 Communication & Publications Report ....................................................................................................................................... 12 PSI/EFSPI Regulatory Report .....................................................................................................................................................
    [Show full text]
  • 2015 Annual Review
    2015 ANNUAL REVIEW PFIZER 2015 ANNUAL REVIEW www.pfizer.com/annual Homepage 1 2015 ANNUAL REVIEW 2015: A TRANSFORMATIONAL YEAR 2015 was a transformational year for Pfizer in our journey to achieve our stated mission: to be the premier, innovative biopharmaceutical company in our industry by the end of this decade. Ian C. Read Chairman & CEO TO OUR STAKEHOLDERS: Innovation, commitment, quality and integrity are the hallmarks of our business, from the development of innovative new products to the delivery of new therapies to patients. Thanks to the more than 97,000 Pfizer colleagues around the world we met our yearly commitments and continued to build the company’s capabilities toward our goal to become the world’s premier, innovative biopharmaceutical company by the end of this decade. PFIZER 2015 ANNUAL REVIEW www.pfizer.com/annual CEO Letter > Letter to Stakeholders 2 2015 ANNUAL REVIEW Notably, in 2015, Pfizer achieved its first year of operational revenue growth since 2009. This occurred largely due to the strong performance of new product launches and OUR PURPOSE despite facing several difficult challenges including overcoming another $3.2 billion in losses of exclusivity, the slowdown in several global markets, and the continued pressure INNOVATE TO BRING THERAPIES TO PATIENTS on access and pricing for our medicines. Our return to operational revenue growth is a THAT SIGNIFICANTLY IMPROVE THEIR LIVES sign that our efforts to speed up innovation are taking hold. In 2015, we also took transformative steps to position Pfizer for the future with the acquisition of Hospira, Inc. and our pending combination with Allergan.
    [Show full text]
  • Downloadedfrom the SGM Invertebrates), Consideri Ng Involvement in Microbiology, the Nu M Ber of Staffand Applicationforms for These
    SGMHeadquarters MarlboroughHouse, Articles BasingstokeRoad, Spencers Wood,Reading RG7 l AG Clinicalmicrobiology:a new golden age? Tel. 011BgBB1800 StephenGillespie Fax 01 189885656 Whatmakes a pathogen? emailmtoday@sg m.ac.uk C,Anthony Hart & CraigWinstanley SGMWebsite http:./wwwsgm.ac.uk Theenemy within - hospital-acquired, antibiotic- Editor resistantbacteria Peter Hawkey Dr MerielJones Fungalinfections in the immunocompromised EditorialBoard MarcMendelson ProfessorDave Kelly 10 Dr LynneMacaskie Theuse of moleculartechniquesto detect antimicrobial ManagingEditor resistanceinclinical bacterial isolates Janet Hurst Ad C,Fluit&Franz-Josef Schmib. 1At+ Produc{ion Editor lanAtherton Howtechnology drives pathogen d iscovery PauI Kellam& Robin Assistant Editor and A, Weiss to Book Review Manager {n Microbiology before Pasteur M i lto n Wai n w ri g ht It, JaniceMeekings parasites - Gontributions Protozoan inthe UK causefor concern? These are alwayswelcome and TimMcHugh oo shouldbe addressedto the Editor (c/o SGM Headquarters). GopyDates Last dates for receiptof copy Regular Features at MarlborouohHouse are: SocietyNews oeneral uoDV Mav2001issue2Aoril November Counci IMeeting 24 August2O0l issue29 May Nominationsfor Members of Council 24 Advertisements (CRC) Above:The risein (pp.1 - 15) describe how NewYearsHonours 24 May2001 issue30April OA hospital-acouired i nfection. newmethods can speed up NewontheSGMwebsite z+ August200 1 issue 25 June Howserious is the ihreat to theirdetection, StaffNews OA Advertisements ourhealth care? NewGroup Conveners
    [Show full text]
  • Voriconazole (Vfend): Risk of Phototoxicity, Skin
    April 2014 Voriconazole (Vfend®): risk of phototoxicity, skin squamous cell carcinoma and liver toxicity – introducing tools to manage these risks. Dear Healthcare Professional Pfizer, in collaboration with the European Medicines Agency (EMA) and MHRA would like to inform you of the following: Summary Voriconazole is associated with a risk of phototoxicity and skin squamous cell carcinoma (SCC). It is therefore important to adhere to the advice on the precautions against phototoxic reactions and monitoring for SCC given in the product information. If phototoxic reactions occur, refer the patient to consult a dermatologist and consider stopping voriconazole treatment If voriconazole treatment is continued despite a phototoxic reaction, the skin should be checked frequently and thoroughly to detect and manage pre- cancerous lesions as early as possible. Stop voriconazole treatment if pre- cancerous skin lesions or SSC are identified Voriconazole is also associated with a risk of liver toxicity. Advice on monitoring liver function in the product information has been revised. It is also important to adhere to this advice. Further information Voriconazole is an antifungal medicine used to treat adults and children over the age of two years with worsening, possibly life-threatening fungal infections. A risk minimization programme has been developed to help manage the aforementioned risks in all patients, including children, taking voriconazole. This programme includes the following documents which are enclosed in this letter: 1. Healthcare Professionals’ Q&A Brochure: Explains the risks of phototoxicity, skin SCC and liver toxicity associated with voriconazole Recommends how to monitor and manage these risks Reminds to use the HCP Checklist and Patient Alert Card, and how to obtain additional copies 2.
    [Show full text]
  • Driving Global Competitiveness of the UK's Life Sciences Ecosystem Document Number PP-PFE-GBR-0391
    Driving Global Competitiveness of the UK’s Life Sciences Ecosystem For the benefit of UK patients, the economy and the NHS PP-PFE-GBR-0391 April 2017 Foreword Erik Nordkamp, Managing Director, Pfizer UK Today every one of the top 20 global of global R&D, especially in high value, late stage pharmaceutical firms has a presence in the UK, R&D, is in patient access to the best medical investing billions of pounds in research and treatments. This analysis tells us that it is the third development, creating tens of thousands of jobs, most important factor in making investment making a significant contribution to the health and decisions and the UK trails significantly behind. wealth of the UK. The encouraging conclusion of this analysis is that Pfizer commissioned this analysis to inform our reducing this access gap could lead to an response to the Government’s Industrial Strategy estimated additional £705m in GVA per year and consultation as it looks to strengthen a globally 4000 jobs, many of which would be high skilled competitive UK life sciences sector. As a global jobs in the UK life sciences sector; generating an company we see many emerging and developed estimated additional £244m in tax (which benefits economies increasingly grow and strengthen their the NHS); and giving UK patients better access to medical R&D capabilities. Some of those countries the latest medical innovations. are benchmarked in this analysis – US, Singapore and Switzerland. This is a prize worth aspiring to and we as industry are committed to working with the Government and This analysis tells us that to have a competitive life the NHS to make sure the UK remains a global sciences sector a holistic ecosystem is needed.
    [Show full text]